{"id":7186,"date":"2021-01-04T17:23:27","date_gmt":"2021-01-04T16:23:27","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=7186"},"modified":"2021-01-04T17:31:55","modified_gmt":"2021-01-04T16:31:55","slug":"7186","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/7186\/","title":{"rendered":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council"},"content":{"rendered":"

\"\"<\/p>\n

Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council<\/strong><\/p>\n

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company\u2019s lead product, for the treatment of severe forms of COVID-19 has been declared \u201cNational Priority Research\u201d by the French government\u2019 steering committee for therapeutic clinical trials and other research (CAPNET).<\/p>\n

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. The \u201cNational Priority Research\u201d designation, granted by CAPNET on the basis of assessment conducted by the REACTing Scientific Council, facilitates accelerated enrollment of patients in clinical trials, the activation of fast-track reviews and approval processes conducted by the French regulatory authorities (ANSM) and the French Ethics committee (CPP), and for better valuing research centers\u2019 active contribution.<\/p>\n

Inotrem\u2019s Phase IIa clinical trial which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company\u2019s lead product, in critically ill COVID-19 patients. This Phase IIa trial follows a preliminary study conducted by Prof. S\u00e9bastien Gibot at the CHU of Nancy, which showed that the TREM-1 pathway was activated in critically ill COVID-19 patients and associated with outcome. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21. 2020 the continuation of Inotrem\u2019s Phase IIa clinical trial which results are expected early Q2 2021.<\/p>\n

Jean-Jacques Garaud, CEO of Inotrem, indicates: \u201cThis Research National Priority designation is an endorsement of both the work we have accomplished so far in fighting the COVID-19 pandemic and of the high potential of our lead product, nangibotide, for treating patients in ICU suffering from severe forms of COVID-19. Thanks to the strong commitment of regulatory bodies and the funding provided by Bpifrance, France\u2019s public investment bank, we were able with our partners, <\/em>CHRU of Nancy and CHU of Limoges, to launch this study in timely manner. This governmental designation will allow us to accelearate this study and more rapidly assess the therapeutic potential for patients suffering from severe forms of <\/em>COVID-19\u201d.<\/em><\/p>\n

Prof. Sebastien Gibot, lead study investigator, adds: \u00ab\u00a0We are very pleased with this decision which will allow us to accelerate patients\u2019 enrollment in France; we plan on enrolling a total of 60 patients. Results of the study are expected early Q2 2021 and <\/em>will determine the safety, tolerability and potential signals of efficacy of nangibotide in COVID-19 patients. Previous clinical studies have demonstrated nangibotide\u2019s safety and tolerability in patients suffering from septic shock, which is also characterized by acute inflammatory syndromes\u201d. <\/em><\/p>\n

In parallel, Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in six European countries and in the United States. Previous clinical studies with nangibotide in septic shock demonstrated that it was safe, well tolerated and showed signals towards clinically relevant efficacy. Pre-clinical models have shown that nangibotide modulates the amplification of the immune response caused by the activation of TREM-1 and is able to restore appropriate inflammatory response and vascular function, resulting in improved survival in septic shock models.<\/p>\n","protected":false},"excerpt":{"rendered":"

Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company\u2019s lead product, for the treatment of severe forms of COVID-19 has been…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-7186","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\nInotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/7186\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company\u2019s lead product, for the treatment of severe forms of COVID-19 has been...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/7186\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-04T16:23:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-04T16:31:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council\",\"datePublished\":\"2021-01-04T16:23:27+00:00\",\"dateModified\":\"2021-01-04T16:31:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/\"},\"wordCount\":582,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/7186\/\",\"name\":\"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png\",\"datePublished\":\"2021-01-04T16:23:27+00:00\",\"dateModified\":\"2021-01-04T16:31:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/7186\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/7186\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/7186\/","og_locale":"en_US","og_type":"article","og_title":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS","og_description":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company\u2019s lead product, for the treatment of severe forms of COVID-19 has been...","og_url":"https:\/\/www.anderapartners.com\/en\/7186\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2021-01-04T16:23:27+00:00","article_modified_time":"2021-01-04T16:31:55+00:00","og_image":[{"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png","type":"","width":"","height":""}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/7186\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council","datePublished":"2021-01-04T16:23:27+00:00","dateModified":"2021-01-04T16:31:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/"},"wordCount":582,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/7186\/","url":"https:\/\/www.anderapartners.com\/en\/7186\/","name":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png","datePublished":"2021-01-04T16:23:27+00:00","dateModified":"2021-01-04T16:31:55+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/7186\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/7186\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/en\/7186\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2021\/01\/INOTREM_Logo-Gris.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/7186\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Inotrem\u2019s COVID-19 Phase IIa Clinical Trial declared \u201cNational Priority Research\u201d by the French government\u2019s Clinical Trial Council"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=7186"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/7186\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=7186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=7186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}